日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma

MYC 依赖的从头丝氨酸和甘氨酸合成途径上调是 3 组髓母细胞瘤中可靶向的代谢弱点

期刊:Neuro-Oncology
影响因子:16.4
doi:10.1093/neuonc/noae179
Magretta Adiamah, Bethany Poole, Janet C Lindsey, Sarah Kohe, Alaide Morcavallo, Florence Burté, Rebecca M Hill, Helen Blair, Dean Thompson, Mankaran Singh, Shanel Swartz, Stephen Crosier, Tong Zhang, Oliver D K Maddocks, Andrew Peet, Louis Chesler, Ian Hickson, Ross J Maxwell, Steven C Clifford
代谢
其它细胞
发表日期：2025
文献求助 收藏

Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers

靶向 Mre11 可克服铂类耐药性并在 XRCC1 缺陷型上皮性卵巢癌中诱导合成致死

期刊:npj Precision Oncology
影响因子:6.8
doi:10.1038/s41698-022-00298-0
Adel Alblihy, Reem Ali, Mashael Algethami, Ahmed Shoqafi, Michael S Toss, Juliette Brownlie, Natalie J Tatum, Ian Hickson, Paloma Ordonez Moran, Anna Grabowska, Jennie N Jeyapalan, Nigel P Mongan, Emad A Rakha, Srinivasan Madhusudan
肿瘤
卵巢癌
发表日期：2022
文献求助 收藏

Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer

发现新一代雄激素受体拮抗剂 JNJ-63576253，可对抗转移性去势抵抗性前列腺癌中的野生型和临床相关配体结合域突变

期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-20-0510
Jonathan R Branch, Tammy L Bush, Vineet Pande, Peter J Connolly, Zhuming Zhang, Ian Hickson, Janine Ondrus, Steffen Jaensch, James R Bischoff, Georges Habineza, Geert Van Hecke, Lieven Meerpoel, Kathryn Packman, Christopher J Parrett, Yolanda T Chong, Marco M Gottardis, Gilles Bignan
肿瘤
前列腺癌
ICC-IF
发表日期：2021
文献求助 收藏

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers

FEN1 阻断对上皮性卵巢癌的铂化疗增敏和合成致死率的影响

期刊:Cancers
影响因子:
doi:10.3390/cancers13081866
Katia A Mesquita, Reem Ali, Rachel Doherty, Michael S Toss, Islam Miligy, Adel Alblihy, Dorjbal Dorjsuren, Anton Simeonov, Ajit Jadhav, David M Wilson 3rd, Ian Hickson, Natalie J Tatum, Emad A Rakha, Srinivasan Madhusudan
肿瘤
卵巢癌
发表日期：2021
文献求助 收藏

USP45 deubiquitylase controls ERCC1-XPF endonuclease-mediated DNA damage responses

USP45 去泛素化酶控制 ERCC1-XPF 内切酶介导的 DNA 损伤反应

期刊:EMBO Journal
影响因子:9.4
doi:10.15252/embj.201489184
Ana B Perez-Oliva, Christophe Lachaud, Piotr Szyniarowski, Ivan Muñoz, Thomas Macartney, Ian Hickson, John Rouse, Dario R Alessi
表观遗传
发表日期：2015
文献求助 收藏

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity

发现 4-{4-[(3R)-3-甲基吗啉-4-基]-6-[1-(甲基磺酰基)环丙基]嘧啶-2-基}-1H-吲哚 (AZ20)：一种强效且选择性的 ATR 蛋白激酶抑制剂，具有单一疗法体内抗肿瘤活性

期刊:Journal of Medicinal Chemistry
影响因子:6.8
doi:10.1021/jm301859s
Kevin M Foote, Kevin Blades, Anna Cronin, Shaun Fillery, Sylvie S Guichard, Lorraine Hassall, Ian Hickson, Xavier Jacq, Philip J Jewsbury, Thomas M McGuire, J Willem M Nissink, Rajesh Odedra, Ken Page, Paula Perkins, Abid Suleman, Kin Tam, Pia Thommes, Rebecca Broadhurst, Christine Wood
肿瘤
发表日期：2013
文献求助 收藏

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

AZD8055 是一种强效、选择性、口服生物利用度高的 ATP 竞争性哺乳动物雷帕霉素激酶抑制剂，具有体外和体内抗肿瘤活性

期刊:Cancer Research
影响因子:12.5
doi:10.1158/0008-5472.CAN-09-1751
Christine M Chresta, Barry R Davies, Ian Hickson, Tom Harding, Sabina Cosulich, Susan E Critchlow, John P Vincent, Rebecca Ellston, Darren Jones, Patrizia Sini, Dominic James, Zoe Howard, Phillippa Dudley, Gareth Hughes, Lisa Smith, Sharon Maguire, Marc Hummersone, Karine Malagu, Keith Menear, Richa
肿瘤
发表日期：2010
文献求助 收藏